{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:59Z","timestamp":1753891979135,"version":"3.41.2"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>COVID-19 immediately became a major consideration in the management of chronic myeloid leukemia (CML). The influence of such considerations on viral transmission rates and leukemic control remain to be explored. We conducted this study to identify these alterations and to investigate their clinical consequences.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a cross-sectional study, performed at a single institution on CML patients who were interviewed with a survey. We compared variables concerning new attitudes in the pandemic era between the 12-month periods before and after the pandemic onset. Outcome data were attained from the hospital archives.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>The number of patients receiving regular outpatient care for CML in chronic phase was 210, 91% had achieved at least major molecular responses. We assessed survival, progression, number of clinical visits of all, performed the survey on 89% and evaluated molecular responses on 86.6% of these patients. The frequency of clinical and molecular monitoring was significantly reduced during the pandemic deviating significantly from the guidelines. Frequency of death, progression, loss of molecular response was not significantly increased during the pandemic era despite a few cases where the delay in assessment possibly played a role in the unfavorable outcomes. There were no COVID related deaths or disabilities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The case-based untoward events would have probably been better managed with a more efficient communication web between patients, hematologists, and the laboratory. Therefore, it seems reasonable to consider whether such communicative paths are functional before giving up on the set schedule of CML management at times of uncertainty.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.994101","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T11:22:34Z","timestamp":1665055354000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of the COVID-19 pandemic on the regular follow-up and outcomes of patients with chronic myeloid leukemia in chronic-phase"],"prefix":"10.3389","volume":"12","author":[{"given":"Umut","family":"Y\u0131lmaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selin","family":"K\u00fc\u00e7\u00fckyurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serta\u00e7","family":"Tun\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet Emre","family":"E\u015fkazan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.220","article-title":"Models of care for chronic myeloid leukemia patients during the COVID-19 pandemic in the united kingdom: Changes in patient attitudes to remote consultations and future implications","volume":"2","author":"Duncan","year":"2021","journal-title":"EJHaem"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2020.031","article-title":"SARS-CoV-2 (COVID-19) and chronic myeloid leukemia (CML): A case report and review of ABL kinase involvement in viral infection","volume":"12","author":"Abruzzese","year":"2020","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17890","article-title":"COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy","volume":"196","author":"Breccia","year":"2022","journal-title":"A Campus CML Rep Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4274\/tjh.galenos.2020.2020.0472","article-title":"COVID-19 in chronic-phase chronic myeloid leukemia patients: A single-center survey from Turkey","volume":"38","author":"Y\u0131lmaz","year":"2021","journal-title":"Turkish J Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/2Fblood-2020-140161","article-title":"COVID-19 in patients (pts) with chronic myeloid leukemia (CML): results from the international CML foundation (iCMLf) CML and COVID-19 (CANDID) study","volume":"136","author":"Rea","year":"2020","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1950709","article-title":"COVID-19 in chronic myeloid leukemia patients in Latin America","volume":"62","author":"Pagnano","year":"2021","journal-title":"Leuk Lymph"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18001","article-title":"Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors","volume":"197","author":"Claudiani","year":"2021","journal-title":"Br J haematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/bjh.17568","article-title":"Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia","volume":"194","author":"Harrington","year":"2021","journal-title":"Br J Haematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-021-01169-w","article-title":"What do we currently know about chronic myeloid leukemia (CML) and COVID-19","volume":"26","author":"Delgado","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17927","article-title":"Is COVID-19 less severe in CML patients than in those with other haematological cancers","volume":"196","author":"Claudiani","year":"2021","journal-title":"Br J haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01428","article-title":"Tyrosine kinase inhibitors play an antiviral action in patients affected by chronic myeloid leukemia: A possible model supporting their use in the fight against SARS-CoV-2","volume":"10","author":"Galimberti","year":"2020","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1813564","article-title":"Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years","volume":"13","author":"Yilmaz","year":"2020","journal-title":"Expert Rev Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.994101\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T11:22:36Z","timestamp":1665055356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.994101\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":13,"alternative-id":["10.3389\/fonc.2022.994101"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.994101","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"article-number":"994101"}}